MERIT MEDICAL SYSTEMS INC (MMSI): Results of Operations and Financial Condition
MERIT MEDICAL SYSTEMS INC (MMSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare +1-801-432-2864 +1-443-213-0509 sarah.comstock@merit.com mike.piccinino@icrhealthcare.com FOR IMMEDIATE
How this was made
The 30-second read
Why it matters
Key decision inputs are the reported Q2 financials (revenue, margins, GAAP and non-GAAP EPS) and the stated increase to 2026 revenue and non-GAAP EPS guidance, alongside cash flow and free cash flow year-to-date declines.
Market read
Guidance increases plus margin and EPS improvement are likely to drive repricing of FY 2026 expectations, while weaker cash flow may create a two-sided reaction.
What to watch
The release references a strategic divestiture impact and excludes potential trade-policy effects from guidance; traders may discount guidance quality if macro or policy risks materialize.
Merit Medical reports second-quarter revenue growth, higher GAAP and non-GAAP margins, and increased full-year 2026 revenue and non-GAAP EPS guidance.
Second-quarter reported revenue rose 10%, both GAAP and non-GAAP operating margins improved, GAAP EPS increased 20%, non-GAAP EPS increased 18%, and the company raised its full-year revenue and non-GAAP EPS guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, three months ended June 30, 2026GAAP | $418,843 (in thousands) | – | 10% |
| Constant currency revenue, three months ended June 30, 2026non-GAAP | $415,856 (in thousands) | – | 9% |
| Constant currency revenue, organic, three months ended June 30, 2026non-GAAP | up 9% | – | up 9% |
| Total revenue, six months ended June 30, 2026GAAP | $800,720 (in thousands) | – | 9% |
| Constant currency revenue, six months ended June 30, 2026non-GAAP | $789,797 (in thousands) | – | 7% |
| GAAP gross marginGAAP | 51.4% | – | – |
| Non-GAAP gross marginnon-GAAP | 55.8% | – | – |
| GAAP operating marginGAAP | 14.4% | – | – |
| Non-GAAP operating marginnon-GAAP | 22.6% | – | – |
| GAAP net incomeGAAP | $38.8 million | – | – |
| GAAP EPSGAAP | $0.65 per share | – | 20% |
| Non-GAAP net incomenon-GAAP | $71.3 million | – | – |
| Non-GAAP EPSnon-GAAP | $1.19 per share | – | 18% |
| Cash flow from operations, year-to-dateGAAP | $110.0 million | – | down 11% |
| Free cash flow generation, year-to-datenon-GAAP | $76.6 million | – | down 14% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Foundational Access, three months ended June 30, 2026Not disclosed. | $161,786 (in thousands) | – | 6% |
| Foundational OEM, three months ended June 30, 2026Not disclosed. | $48,338 (in thousands) | – | 12% |
| Foundational Procedural Solutions, three months ended June 30, 2026Not disclosed. | $27,949 (in thousands) | – | (12)% |
| Foundational Vascular Intervention, three months ended June 30, 2026Not disclosed. | $41,652 (in thousands) | – | 19% |
| Foundational Other, three months ended June 30, 2026Not disclosed. | $1,236 (in thousands) | – | 257% |
| Total Foundational, three months ended June 30, 2026Not disclosed. | $280,961 (in thousands) | – | 7% |
| Therapeutic Cardiac Therapies, three months ended June 30, 2026Not disclosed. | $28,510 (in thousands) | – | 24% |
| Therapeutic Endoscopy, three months ended June 30, 2026Not disclosed. | $23,647 (in thousands) | – | 29% |
| Therapeutic OEM, three months ended June 30, 2026Not disclosed. | $12,797 (in thousands) | – | 31% |
| Therapeutic Oncology, three months ended June 30, 2026Not disclosed. | $25,774 (in thousands) | – | 8% |
| Therapeutic Renal Therapies, three months ended June 30, 2026Not disclosed. | $12,713 (in thousands) | – | (1)% |
| Therapeutic Vascular Intervention, three months ended June 30, 2026Not disclosed. | $34,441 (in thousands) | – | 7% |
| Total Therapeutic, three months ended June 30, 2026Not disclosed. | $137,882 (in thousands) | – | 15% |
| Total Foundational, six months ended June 30, 2026Not disclosed. | $536,440 (in thousands) | – | 7% |
| Total Therapeutic, six months ended June 30, 2026Not disclosed. | $264,280 (in thousands) | – | 12% |
Year ending December 31, 2026 outlook
- Revenue$1.631 - $1.643 billion
- NoteTotal revenue: 8% - 8% Y/Y
- NoteNon-GAAP Earnings Per Share: $4.25 - $4.35
- NoteNon-GAAP Earnings Per Share: 11% - 14% Y/Y
- NoteNon-GAAP earnings per share reflect the dilutive impact of the 3.00% Convertible Senior Notes due 2029 calculated using the if-converted method of approximately $0.03 per share for the year ending December 31, 2026.
What drove it
- Reported revenue increased 10%, while constant currency revenue and constant currency revenue, organic each increased 9%.
- Sales to customers in the U.S. increased 10% year-over-year, according to management.
- Total Therapeutic revenue increased 15%, led by Endoscopy growth of 29%, Cardiac Therapies growth of 24%, and Therapeutic OEM growth of 31%.
- Total Foundational revenue increased 7%, supported by Foundational Vascular Intervention growth of 19% and Foundational OEM growth of 12%.
- Management cited the exclusion of the impact of a strategic divestiture in describing organic, constant currency revenue growth.
Concerns
- Foundational Procedural Solutions revenue declined 12% year-over-year in the second quarter.
- Therapeutic Renal Therapies revenue declined 1% year-over-year in the second quarter.
- Year-to-date cash flow from operations was down 11%, and year-to-date free cash flow generation was down 14%.
- Full-year guidance excludes the potential impact of trade policies and related actions implemented by the U.S. and other countries subsequent to July 30, 2026, material acquisitions, non-recurring transactions, and other factors beyond Merit’s current expectations.
What to watch
- Execution against updated full-year total revenue guidance of $1.631 - $1.643 billion.
- Delivery against updated full-year non-GAAP earnings per share guidance of $4.25 - $4.35.
- Whether improving growth trends across the global business and strength in U.S. customer sales continue.
- Progress in Procedural Solutions and Renal Therapies following their second-quarter revenue declines.
- Cash flow performance following year-to-date declines in cash flow from operations and free cash flow generation.
- Progress toward the Continued Growth Initiative financial targets for the three-year period ending December 31, 2026.
Balance sheet and cash flow
- Cash and cash equivalents were $448.7 million as of June 30, 2026, compared to $446.4 million as of December 31, 2025.
- Total debt obligations were $747.5 million as of June 30, 2026, compared to $747.5 million as of December 31, 2025.
- Available borrowing capacity was approximately $697 million as of June 30, 2026.
- Trade receivables, net were $224,237 (in thousands) as of June 30, 2026, compared to $203,710 (in thousands) as of December 31, 2025.
- Inventories were $374,112 (in thousands) as of June 30, 2026, compared to $333,705 (in thousands) as of December 31, 2025.
- Total assets were $2,863,620 (in thousands) as of June 30, 2026, compared to $2,685,922 (in thousands) as of December 31, 2025.
- Cash flow from operations was $110.0 million year-to-date, down 11%.
- Free cash flow generation was $76.6 million year-to-date, down 14%.
Analysis
Merit reported second-quarter revenue of $418,843 (in thousands), up 10% from $382,462 (in thousands). Constant currency revenue was $415,856 (in thousands), up 9%, and the company reported constant currency revenue, organic growth of 9%. Management said results exceeded the high end of its expectations and cited improving global revenue trends and a 10% year-over-year increase in sales to U.S. customers.
Growth was broad but uneven across product categories. Total Foundational revenue increased 7%, with Access up 6%, OEM up 12%, and Vascular Intervention up 19%, partly offset by a 12% decline in Procedural Solutions. Total Therapeutic revenue increased 15%, paced by Endoscopy growth of 29%, Cardiac Therapies growth of 24%, and Therapeutic OEM growth of 31%. Renal Therapies declined 1%.
Profitability improved across reported margin measures. GAAP gross margin increased to 51.4% from 48.2%, and non-GAAP gross margin increased to 55.8% from 53.2%. GAAP operating margin increased to 14.4% from 12.3%, while non-GAAP operating margin increased to 22.6% from 21.2%. GAAP net income was $38.8 million, or $0.65 per share, and non-GAAP net income was $71.3 million, or $1.19 per share.
Cash flow was softer on a year-to-date basis, with cash flow from operations of $110.0 million, down 11%, and free cash flow generation of $76.6 million, down 14%. Cash and cash equivalents were $448.7 million, total debt obligations were $747.5 million, and available borrowing capacity was approximately $697 million as of June 30, 2026. Inventories were $374,112 (in thousands), compared with $333,705 (in thousands) as of December 31, 2025.
The company increased full-year 2026 total revenue guidance to $1.631 - $1.643 billion from the prior guidance range of $1.612 - $1.634 billion presented in the release. It increased non-GAAP earnings per share guidance to $4.25 - $4.35 from $4.01 - $4.15. The guidance is subject to stated risks including potential trade-policy actions, material acquisitions, non-recurring transactions, and other factors beyond current expectations.
Management, verbatim
Merit delivered second quarter financial results that exceeded the high end of our expectations, driven primarily by 9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture.
Martha G. Aronson, President and CEO
We experienced improving revenue growth trends across our global business in Q2, as expected, with notable strength in sales to customers in the U.S. which increased 10% year-over-year, well ahead of our expectations.
Martha G. Aronson, President and CEO
We have increased our 2026 revenue and non-GAAP earnings per share guidance to reflect the stronger-than-expected results over the first half of 2026 and remain confident in our team’s ability to execute, with attractive constant currency growth, improving profitability, and solid cash flow generation this year.
Martha G. Aronson, President and CEO
Not in the filing
stated, not guessed- Absolute GAAP gross profit for the second quarter was not provided in the supplied text.
- Absolute non-GAAP gross profit for the second quarter was not provided in the supplied text.
- Absolute GAAP operating income for the second quarter was not provided in the supplied text.
- Absolute non-GAAP operating income for the second quarter was not provided in the supplied text.
- Quarterly operating cash flow was not provided in the supplied text.
- Quarterly free cash flow was not provided in the supplied text.
- Operating expenses were not provided in the supplied text.
- Tax rate was not provided in the supplied text.
- Share repurchases, dividends, and other capital-return activity were not provided in the supplied text.
- A separately supplied previous-release outlook section was not provided; therefore, no actual-versus-prior-guidance comparison is included.
- CFO commentary was not provided in the supplied text.
- Second-quarter revenue by geographic region, other than management’s statement that U.S. customer sales increased 10% year-over-year, was not provided in the supplied text.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is Merit Medical Systems, Inc. (MMSI) reporting Q2 2026 results via SEC Form 8-K (Item 2.02) and updating full-year 2026 guidance.
Ticker impact
Merit Medical reported Q2 2026 revenue of $418.8M (+10% YoY) and raised full-year 2026 revenue and non-GAAP EPS guidance.
Near-term positive bias as traders reprice FY 2026 revenue and non-GAAP EPS expectations; follow-through depends on whether cash flow weakness offsets earnings strength.
The filing includes multiple quantified beats (revenue, GAAP and non-GAAP EPS, operating margins) plus explicit guidance increases, which are direct inputs to valuation and positioning.
Market effects
Signals improving demand and profitability trends in medical device equipment, potentially supporting sentiment toward medtech peers with similar procedure and endoscopy exposure.
U.S. sales strength (up 10% YoY) may reinforce expectations for domestic procedure volumes.
Constant-currency growth and foreign-exchange impacts are quantified, informing how global demand is trending versus FX noise.
Counterpoint
Cash flow from operations and free cash flow are down year-to-date, which could temper enthusiasm if investors prioritize cash conversion over earnings.
Key entities
- companyMerit Medical Systems, Inc.
NASDAQ-listed medical technology manufacturer reporting Q2 2026 results and updated FY 2026 guidance.
- executiveMartha G. Aronson
President and CEO quoted discussing organic growth, margin improvement, and guidance increases.
